This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.
Study Type
OBSERVATIONAL
Enrollment
2,297
Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
Unnamed facility
Many Locations, Hong Kong
Unnamed facility
Many Locations, India
Unnamed facility
Many Locations, Indonesia
Unnamed facility
Many Locations, Malaysia
Adjudicated major bleeding events
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Safety variables will be summarized using descriptive statistics based on adverse events collection
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
All cause mortality
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Adjudicated symptomatic thromboembolic events
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Non-major bleeding, collected as SAEs or non-serious AEs and defined as all bleeding events that do not fall in the category of major bleedings
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Treatment satisfaction as per patient assessment of rivaroxaban treatment by the physician at the final visit
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Healthcare resource
Number of healthcare professional visits and hospitalizations due to anticoagulation
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Adverse events rates in the different AF risk factor categories
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Many Locations, Pakistan
Unnamed facility
Many Locations, Philippines
Unnamed facility
Many Locations, Singapore
Unnamed facility
Many Locations, South Korea
Unnamed facility
Many Locations, Taiwan
Unnamed facility
Many Locations, Thailand
...and 1 more locations
Persistence with rivaroxaban treatment measured as percentage of patients on rivaroxaban treatment at 1 year after start of study treatment
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Reasons for switch of rivaroxaban treatment as per physician assessment during or at end of study
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Reasons for interruption of rivaroxaban treatment as per physician assessment during or at end of study
Time frame: after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later